Rapid methods for determination of fluoxetine in pharmaceutical formulations

Polythiophene-Chitosan Magnetic Nanocomposite as a Highly Efficient Medium for Isolation of Fluoxetine from Aqueous and Biological Samples

Polythiophene/chitosan magnetic nanocomposite as an adsorbent of magnetic solid phase extraction was proposed for the isolation of fluoxetine in aqueous and biological samples prior to fluorescence detection at 246 nm. The synthesized nanoparticles, chitosan and polythiophene magnetic nanocomposite, were characterized by scanning electron microscopy, FT-IR, TGA, and EDAX. The separation of the target analyte from the aqueous solution containing the fluoxetine and polythiophene/chitosan magnetic nanocomposite was simply achieved by applying external magnetic field. The main factors affecting the extraction efficiency including desorption conditions, extraction time, ionic strength, and sample solution pH were optimized. The optimum extraction conditions were obtained as 10 min for extraction time, 25 mg for sorbent amount, 50 mL for initial sample volume, methanol as desorption solvent, 1.5 mL for desorption solvent volume, 3 min for desorption time, and being without salt addition. Under the optimum conditions, good linearity was obtained within the range of 15-1000 μg L(-1) for fluoxetine, with correlation coefficients 0.9994. Furthermore, the method was successfully applied to the determination of fluoxetine in urine and human blood plasma samples. Compared with other methods, the current method is characterized with highly easy, fast separation and low detection limits.

New spectrophotometric and fluorimetric methods for determination of fluoxetine in pharmaceutical formulations

New simple and sensitive spectrophotometric and fluorimetric methods have been developed and validated for the determination of fluoxetine hydrochloride (FLX) in its pharmaceutical formulations. The spectrophotometric method was based on the reaction of FLX with 1,2-naphthoquinone-4-sulphonate (NQS) in an alkaline medium (pH 11) to form an orange-colored product that was measured at 490 nm. The fluorimetric method was based on the reaction of FLX with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) in an alkaline medium (pH 8) to form a highly fluorescent product that was measured at 545 nm after excitation at 490 nm. The variables affecting the reactions of FLX with both NQS and NBD-Cl were carefully studied and optimized. The kinetics of the reactions were investigated, and the reaction mechanisms were presented. Under the optimum reaction conditions, good linear relationships were found between the readings and the concentrations of FLX in the ranges of 0.3–6 and 0.035–0.5 μg mL⁻¹ for the spectrophotometric and fluorimetric methods, respectively. The limits of detection were 0.1 and 0.01 μg mL⁻¹ for the spectrophotometric and fluorimetric methods, respectively. Both methods were successfully applied to the determination of FLX in its pharmaceutical formulations.

Quality assessment of fluoxetine and fluvoxamine pharmaceutical formulations purchased in different countries or via the Internet by 19F and 2D DOSY 1H NMR

A simple and selective (19)F NMR method has been validated for the quantitation of fluoxetine (FLX) and fluvoxamine (FLV) in methanol solutions and in human plasma and urine. The regression equations for FLX and FLV showed a good linearity in the range of 1.4-620 microg mL(-1) (3.3 x 10(-6)-1.8 x 10(-3) mol L(-1)) with a limit of detection of approximately 0.5 microg mL(-1) (1.3 x 10(-6) mol L(-1)) and a limit of quantification of approximately 2 microg mL(-1) (4.6 x 10(-6) mol L(-1)). The precision of the assay depends on the concentrations and is comprised between 1.5 and 9.5% for a range of concentrations between 1.2 x 10(-3) and 3.2 x 10(-6) mol L(-1). The accuracy evaluated through recovery studies ranged from approximately 96 to 103% in methanol solutions and in urine, and from approximately 93 to 104% in plasma, with standard deviations <7.5%. The low sensitivity of the method precludes its use for the assay of these antidepressants in biofluids at least at therapeutic doses as the ranges of FLX and FLV plasma levels are 0.15-0.5 microg mL(-1) and 0.15-0.25 microg mL(-1), respectively. The method was applied successfully to the determination of FLX and FLV contents in pharmaceutical samples (brand-named and generic) purchased in several countries or via the Internet. All the commercial formulations contain the active ingredient in the range 94-103% of stated concentration. A "signature" of the formulations (solid and liquid) was obtained with 2D Diffusion-Ordered SpectroscopY (DOSY) (1)H NMR which allowed the characterisation of the active ingredient and excipients present in the formulations studied. Finally, the DOSY separation of FLX and FLV whose molecular weights are very close was obtained by using beta-cyclodextrin as host-guest complexing agent.

Determination of antidepressants in surface and waste water samples by capillary electrophoresis with electrospray ionization mass spectrometric detection after preconcentration using off-line solid-phase extraction

A method for the quantitative determination of seven major antidepressants in surface waters and sewage treatment plant effluents by CE using ESI-MS is presented. Calibration curves for the selected analytes were prepared in Milli-Q purified water and Danube river water extract covering a concentration range of at least one order of magnitude. LODs achieved were between 6 and 13 microg/L for Trazodone and 39 and 53 microg/L for Sertraline in the Milli-Q purified water and Danube river water matrix, respectively. For sample preparation eight different SPE materials were investigated. Best results were obtained for a resin based on hydrophilic divinylbenzene (recoveries from Milli-Q purified water 93-96%; from Danube river water 85-99%). Finally, a series of eight sewage treatment plant effluents were investigated with respect to their content in the selected antidepressants. Six of these samples were tested positive for antidepressants, in particular Venlafaxine, Citalopram and Trazodone in concentrations between 36 and 322 ng/L.

Development of an analytical method for the determination of antidepressants in water samples by capillary electrophoresis with electrospray ionization mass spectrometric detection

A method for the quantitative determination of major antidepressants in aqueous matrices by CE using ESI-MS is presented. Several aqueous, nonaquoeus, and mixed aqueous/organic solvent BGEs including inorganic and organic acids were investigated with respect to their suitability for the separation of the selected analytes. Finally, due to the necessity to employ MS detection if the developed method should be suitable also for environmental samples, only MS-compatible electrolytes were taken into account. Based on this fact optimum results were obtained with a system consisting of 1.5 M formic acid and 50 mM ammonium formate in ACN/water (85/15). Linear calibration plots could be obtained for all solutes over a concentration range of almost two orders of magnitude, and the LODs achieved were in the range of 3-6 microg/L for trazodone and 39-43 microg/L for sertraline with the TOF instrument and the single quadrupole instrument in the SIM mode, respectively. This fact allowed the assumption that the presented method can be regarded as suitable for the determination of antidepressants even in the trace amounts commonly present in environmental samples. Spiking of river water and sewage plant effluent extracts with the selected solutes showed that no interferences from the matrix usually found in such samples can be expected. Finally the quantitative determination of the seven antidepressants in environmental samples was used to benchmark the performance of CZE coupled to a single quadrupole MS and a TOF-MS.

A capillary zone electrophoresis (CZE) method for the determination of cyclizine hydrochloride in tablets and suppositories

Current compendial methods of assay for the analysis of cyclizine tablets involve the use of UV spectrophotometry. Since this is a non-selective technique its application to more complex dosage forms, such as suppositories, is unlikely to be appropriate. There is therefore a need for the development of a highly specific quantitative analytical method, such as high performance liquid chromatography (HPLC) or capillary electrophoresis (CE). The latter technique was chosen in view of some specific advantages over HPLC, such as the use of relatively non-toxic aqueous buffers, as opposed to organic solvents, which obviates the use of expensive HPLC grade solvents making CE more cost effective. Cyclizine was analyzed in 50mM phosphate buffer (pH 2.3) and run at an applied voltage 25 kV. Detection sensitivity was enhanced by using a wavelength of 200 nm and samples were loaded hydrodynamically onto an uncoated fused-silica capillary (60 cm x 50 mm i.d.). Chlorcyclizine was used as the internal standard and resolution of both compounds was achieved in less than 7 min. Stress testing was undertaken in order to investigate the appearance of breakdown products. The method has the requisite accuracy, selectivity, sensitivity and precision to assay cyclizine in tablets and suppositories. Degradation products resulting from the stress studies did not interfere with the detection of cyclizine and the assay is thus stability-indicating.